Literature DB >> 32435368

AuNP Pyrazolo[3,4-d]pyrimidine Nanosystem in Combination with Radiotherapy against Glioblastoma.

Alessio Molinari1, Giulia Iovenitti1, Arianna Mancini1,2, Giovanni Luca Gravina3, Monia Chebbi1,4, Maura Caruana1, Giulia Vignaroli1, Francesco Orofino1, Enrico Rango1, Adriano Angelucci3, Elena Dreassi1, Silvia Schenone5, Maurizio Botta1,6,7.   

Abstract

Gold-nanoparticle (AuNP)-conjugated drugs represent a promising and innovative antitumor therapeutic approach. In our study, we describe the design, the synthesis, the preparation, and the characterization of AuNPs conjugated with the pyrazolo[3,4-d]pyrimidine derivative SI306, a c-Src inhibitor. AuNPs-SI306 showed a good loading efficacy (65%), optimal stability in polar media and in human plasma, and a suitable morphological profile: a ζ-potential of -43.9 mV, a nanoparticle diameter of 48.6 nm, and a 0.441 PDI value. The antitumoral activity of AuNPs-SI306 was evaluated in vitro in the glioblastoma model, by the low-density growth assay, and also in combination with radiotherapy (RT). Results demonstrated that AuNPs had a basal radiosensitization ability and that AuNPs-SI306, when used in combination with RT, were more effective in inhibiting tumor cell growth with respect to AuNPs and free SI306.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32435368      PMCID: PMC7236040          DOI: 10.1021/acsmedchemlett.9b00538

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  36 in total

1.  Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant.

Authors:  Marco Radi; Cristina Tintori; Francesca Musumeci; Chiara Brullo; Claudio Zamperini; Elena Dreassi; Anna Lucia Fallacara; Giulia Vignaroli; Emmanuele Crespan; Samantha Zanoli; Ilaria Laurenzana; Irene Filippi; Giovanni Maga; Silvia Schenone; Adriano Angelucci; Maurizio Botta
Journal:  J Med Chem       Date:  2013-06-20       Impact factor: 7.446

2.  Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells.

Authors:  Marco Radi; Chiara Brullo; Emmanuele Crespan; Cristina Tintori; Francesca Musumeci; Mariangela Biava; Silvia Schenone; Elena Dreassi; Claudio Zamperini; Giovanni Maga; Dafne Pagano; Adriano Angelucci; Mauro Bologna; Maurizio Botta
Journal:  Bioorg Med Chem Lett       Date:  2011-07-29       Impact factor: 2.823

3.  SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.

Authors:  Elisa Ceccherini; Paola Indovina; Claudio Zamperini; Elena Dreassi; Nadia Casini; Ornella Cutaia; Iris Maria Forte; Francesca Pentimalli; Luca Esposito; Maria Sole Polito; Silvia Schenone; Maurizio Botta; Antonio Giordano
Journal:  J Cell Biochem       Date:  2015-05       Impact factor: 4.429

4.  Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.

Authors:  Alexandros Bouras; Milota Kaluzova; Costas G Hadjipanayis
Journal:  J Neurooncol       Date:  2015-05-17       Impact factor: 4.130

5.  Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.

Authors:  Jennie W Taylor; Jorg Dietrich; Elizabeth R Gerstner; Andrew D Norden; Mikael L Rinne; Daniel P Cahill; Anat Stemmer-Rachamimov; Patrick Y Wen; Rebecca A Betensky; Diana H Giorgio; Kellis Snodgrass; Alison E Randall; Tracy T Batchelor; Andrew S Chi
Journal:  J Neurooncol       Date:  2014-11-20       Impact factor: 4.130

Review 6.  Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Authors:  Manmeet S Ahluwalia; John de Groot; Wei Michael Liu; Candece L Gladson
Journal:  Cancer Lett       Date:  2010-12-08       Impact factor: 8.679

Review 7.  The molecular biology of cancer.

Authors:  J S Bertram
Journal:  Mol Aspects Med       Date:  2000-12

8.  Paclitaxel-functionalized gold nanoparticles.

Authors:  Jacob D Gibson; Bishnu P Khanal; Eugene R Zubarev
Journal:  J Am Chem Soc       Date:  2007-08-24       Impact factor: 15.419

9.  Carbonic anhydrase inhibitor coated gold nanoparticles selectively inhibit the tumor-associated isoform IX over the cytosolic isozymes I and II.

Authors:  Maamar Stiti; Alessandro Cecchi; Marouan Rami; Mohamed Abdaoui; Véronique Barragan-Montero; Andrea Scozzafava; Yannick Guari; Jean-Yves Winum; Claudiu T Supuran
Journal:  J Am Chem Soc       Date:  2008-12-03       Impact factor: 15.419

Review 10.  Glioblastoma: molecular pathways, stem cells and therapeutic targets.

Authors:  Meena Jhanwar-Uniyal; Michael Labagnara; Marissa Friedman; Amanda Kwasnicki; Raj Murali
Journal:  Cancers (Basel)       Date:  2015-03-25       Impact factor: 6.639

View more
  3 in total

Review 1.  Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable.

Authors:  Amir Barzegar Behrooz; Zahra Talaie; Amir Syahir
Journal:  Pharmaceutics       Date:  2022-08-15       Impact factor: 6.525

Review 2.  Nanomaterials as Promising Theranostic Tools in Nanomedicine and Their Applications in Clinical Disease Diagnosis and Treatment.

Authors:  Wei Zhu; Zhanqi Wei; Chang Han; Xisheng Weng
Journal:  Nanomaterials (Basel)       Date:  2021-12-10       Impact factor: 5.076

3.  The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma.

Authors:  Enrico Rango; Fabio Pastorino; Chiara Brignole; Arianna Mancini; Federica Poggialini; Salvatore Di Maria; Claudio Zamperini; Giulia Iovenitti; Anna Lucia Fallacara; Samantha Sabetta; Letizia Clementi; Massimo Valoti; Silvia Schenone; Adriano Angelucci; Mirco Ponzoni; Elena Dreassi; Maurizio Botta
Journal:  Biomedicines       Date:  2022-03-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.